Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06718569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pain in Inflammatory Joint Diseases

Study acronym: Nor-Pain
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2025 to Nov 11, 2025
    • Secondary endpoints: 20 to 23
    v4
  2. Primary and study completion dates: Apr 2027 to Nov 2027
    • Start date: Mar 2025 to Aug 2025
    v3
  3. Start date: Jan 2025 to Mar 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.
Trial Details
NCT Number NCT06718569
Lead Sponsor Diakonhjemmet Hospital
Collaborators: University of Oslo
Conditions
(from sponsor)		 Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid, Arthritis, Reactive, Arthritis, Psoriatic, Spondyloarthritis (SpA)
Related terms Arthritis, Arthritis, Juvenile, Arthritis, Psoriatic, Arthritis, Reactive, Arthritis, Rheumatoid, Spondylarthritis
Enrollment 350 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov